On a tumor growth model with brain lactate kinetics.

Math Med Biol

Laboratoire I3M et Laboratoire de Mathématiques et Applications, Université de Poitiers, UMR CNRS 7348, Equipe DACTIM-MIS, Site du Futuroscope-Téléport 2 11 Boulevard Marie et Pierre Curie-Bâtiment H3-TSA 61125, 86073 Poitiers Cedex 9, France, and CHU de Poitiers, 2 rue de la Milétrie 86000 Poitiers, France.

Published: December 2022

Our aim in this paper is to study a mathematical model for high grade gliomas, taking into account lactates kinetics, as well as chemotherapy and antiangiogenic treatment. In particular, we prove the existence and uniqueness of biologically relevant solutions. We also perform numerical simulations based on different therapeutical situations that can be found in the literature. These simulations are consistent with what is expected in these situations.

Download full-text PDF

Source
http://dx.doi.org/10.1093/imammb/dqac010DOI Listing

Publication Analysis

Top Keywords

tumor growth
4
growth model
4
model brain
4
brain lactate
4
lactate kinetics
4
kinetics aim
4
aim paper
4
paper study
4
study mathematical
4
mathematical model
4

Similar Publications

HIFU induces reprogramming of the tumor immune microenvironment in a pancreatic cancer mouse model.

Med Mol Morphol

January 2025

Faculty of Advanced Techno-Surgery (FATS), Institute of Advanced Biomedical Engineering and Science, Tokyo Women's Medical University, 8-1 Kawada-Cho, Shinjuku, Tokyo, 162-8666, Japan.

This study evaluates the effects of different high-intensity focused ultrasound irradiation (HIFU) methods on local tumor suppression and systemic antitumor effects, including the abscopal effect, in a mouse model of pancreatic cancer. To ascertain the efficacy of the treatment, pancreatic cancer cells were injected into the thighs of mice and HIFU was applied on one side using continuous waves or trigger pulse waves. Then, tumor volume, tissue changes, and immune marker levels were analyzed.

View Article and Find Full Text PDF

Immunity suffers a function deficit during aging, and the incidence of cancer is increased in the elderly. However, most cancer models employ young mice, which are poorly representative of adult cancer patients. We have previously reported that Triple-Therapy (TT), involving antigen-presenting-cell activation by vinorelbine and generation of TCF1-stem-cell-like T cells (scTs) by cyclophosphamide significantly improved anti-PD-1 efficacy in anti-PD1-resistant models like Triple-Negative Breast Cancer (TNBC) and Non-Hodgkin's Lymphoma (NHL), due to T-cell-mediated tumor killing.

View Article and Find Full Text PDF

The main objective of this work is to study the mathematical model that combines stem cell therapy and chemotherapy for cancer cells. We study the model using the fractal fractional derivative with the Mittag-Leffler kernel. In the analytical part, we study the existence of the solution and its uniqueness, which was studied based on the fixed point theory.

View Article and Find Full Text PDF

The role of human epidermal growth factor 2 (HER2) in male breast cancer (MBC) is poorly defined. A comprehensive description of HER2 status was conducted. A total of 6,015 MBC patients from 45 studies and 135 MBC patients with sequencing data were identified.

View Article and Find Full Text PDF

KAT2B inhibits proliferation and invasion via inactivating TGF-β/Smad3 pathway-medicated autophagy and EMT in epithelial ovarian cancer.

Sci Rep

January 2025

Department of Obstetrics and Gynecology, Center for Reproductive Medicine, Affiliated Hospital of North Sichuan Medical College, Nanchong, 637000, Sichuan, People's Republic of China.

Lysine acetyltransferase 2B (KAT2B) plays a crucial role in epigenetic regulation and tumor pathogenesis. Our study investigates KAT2B's function in epithelial ovarian cancer (EOC) using in vivo and in vitro methods. Immunohistochemistry showed the KAT2B expression in EOC tissues.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!